MBRX - Moleculin Biotech, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.2000
-0.1000 (-7.69%)
At close: 4:00PM EDT

1.0500 -0.15 (-12.50%)
After hours: 7:59PM EDT

Stock chart is not supported by your current browser
Previous Close1.3000
Open1.4300
Bid1.0400 x 1000
Ask1.0500 x 3200
Day's Range1.1800 - 1.4800
52 Week Range0.9340 - 2.4300
Volume2,379,301
Avg. Volume167,174
Market Cap34.234M
Beta (3Y Monthly)1.86
PE Ratio (TTM)N/A
EPS (TTM)-0.4580
Earnings DateApr 3, 2019 - Apr 8, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.50
Trade prices are not sourced from all markets
  • PR Newswire3 hours ago

    Moleculin Announces Proposed Underwritten Public Offering

    The Company intends to use the net proceeds of the offering to fund its planned clinical trials, preclinical programs, for other research and development activities and for general corporate purposes. The securities described above are being offered by the Company pursuant to a shelf registration statement on Form S-3 (No. 333-219434) previously filed with and declared effective by the Securities and Exchange Commission (SEC).  A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC's website at http://www.sec.gov.

  • PR Newswire13 hours ago

    Moleculin Announces Positive Interim Results in First Cohort of Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia in the US and in Poland

    HOUSTON, March 26, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced positive interim safety and efficacy data from two ongoing open label, single arm Phase 1/2 studies of Annamycin.  In the first study, being conducted in the US, four patients have completed treatment at 100 mg/m2 with no significant adverse events related to Annamycin, and the study will now proceed to the next higher dose of 120 mg/m2. The second trial, taking place in Poland, started at a 120 mg/m2 dose of Annamycin and has treated three patients.

  • PR Newswire8 days ago

    Moleculin Announces First Patients Enrolled in Lymphoma Clinical Trial

    HOUSTON, March 19, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that the first two patients have been enrolled in its European clinical trial of WP1220 for the topical treatment of cutaneous T-cell lymphoma (CTCL). "This now marks four clinical trials with patients enrolled," commented Walter Klemp, Moleculin's Chairman and CEO. "In this case, we are targeting CTCL with a topical p-STAT3 inhibitor in light of the significant role that STAT3 appears to play in CTCL skin lesions.

  • PR Newswire8 days ago

    Moleculin Announces Memorial Sloan Kettering Chief of Leukemia Joins Science Advisory Board

    HOUSTON , March 18, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug ...

  • PR Newswire9 days ago

    Moleculin Biotech, Inc. to Present at the Oppenheimer 29th Annual Healthcare Conference and the 31st Annual ROTH Conference

    Management will present on Wednesday, March 20, 2019 at 3:20 p.m. ET. The Conference will be held at the Westin New York Grand Central Hotel in New York City. 31st Annual ROTH Conference – Management will be available on Monday, March 18, 2019 for one-on-one meetings with investors.

  • ACCESSWIRE13 days ago

    Moleculin Announces First Patients Treated in European Annamycin Clinical Trial

    HOUSTON, TX / ACCESSWIRE / March 14, 2019 / Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced the first patients have been treated in the Company's second clinical trial to study Annamycin for the treatment of relapsed and refractory adults with acute myeloid leukemia. The Company further reported that the initial treatment of the first patient appeared to be well tolerated.

  • ACCESSWIRE14 days ago

    Moleculin Files with FDA for Expedited Approval Pathway for Annamycin

    HOUSTON, TX / ACCESSWIRE / March 13, 2019 / Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that it has submitted a request for Fast Track Designation with the US Food and Drug Administration (FDA) for its drug, Annamycin, for the treatment of relapsed or refractory acute myeloid leukemia (AML). "Now that we have some traction in our clinical trials of Annamycin for the treatment of relapsed or refractory AML," commented Walter Klemp, Moleculin's Chairman and CEO, "we believe it is appropriate to request Fast Track designation for Annamycin.

  • Benzingalast month

    The Daily Biotech Pulse: BioMarin Slips On Earnings, TherapeuticsMD Posts In-Line Results, Orchard To Present Immunodeficiency Drug Data

    The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 21.) Eli Lilly And Co (NYSE: LLY ) Gossamer ...

  • GlobeNewswirelast month

    Moleculin Biotech, Inc. Reports Financial Results for the Year Ended December 31, 2018

    Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical-stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center, today announced its financial results for the year ended December 31, 2018. Additionally, the Company announced potential upcoming milestones and recent corporate developments. The recent initiation of our WP1220 skin cancer clinical trial in Poland achieves an important milestone - Moleculin now has three unique drug candidates in four ongoing clinical trials.

  • GlobeNewswirelast month

    Moleculin Announces Outlicensing Deal To Accelerate Preclinical and Clinical Development

    Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that it has entered into a sublicense agreement with WPD Pharmaceuticals (WPD), located in Poland. The agreement provides WPD with exclusive rights, subject to current license agreements, to develop and market a range of Moleculin’s technologies in certain European countries (which does not include the UK, France, Italy and Spain) in exchange for contributing a minimum of $4 million in development expenditures agreed upon by Moleculin during the term of the agreement plus an ongoing royalty on future revenues.

  • PR Newswirelast month

    Northern Lights Supply Store in Alberta Receives First Inventory in Preparation for Grand Opening

    VANCOUVER, British Columbia, Feb. 19, 2019 /PRNewswire/ -- Weekend Unlimited Inc. ("Weekend" or the "Company") (CSE:POT) (0OS1.SG)  (WKULF) is pleased to announce that Northern Lights Supply in Nisku, Alberta has received its initial shipment from AGLC allowing it to set a grand opening date for February 23rd. "Having received the store's initial order, we are currently stocking the shelves and conducting our final staff training and systems checks in order to hold our grand opening next week, on February 23rd," said Northern Lights Supply President, Derek Shields.

  • PR Newswirelast month

    Premier Health Provides Corporate Update

    VANCOUVER, British Columbia, Feb. 14, 2019 /PRNewswire/ -- Premier Health Group (CSE:PHGI) (PHGRF) (Frankfurt: 6PH) (the "Company" or "Premier Health"), a Company focused on developing innovative approaches that combine human skill-based expertise with emerging technologies for the healthcare industry, is pleased to provide a corporate update.

  • GlobeNewswire2 months ago

    Moleculin Announces Approval for Third Drug to Commence Clinical Trials

    Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced it has received approval to begin clinical trials in Poland for its STAT3 inhibitor, WP1220, for the topical treatment of Cutaneous T-Cell Lymphoma (“CTCL”). “This marks an important milestone for Moleculin.

  • ACCESSWIRE2 months ago

    4 Healthcare Stocks The Market is Watching on Tuesday (2/5/19)

    CORAL GABLES, FL / ACCESSWIRE / February 5, 2019 / The healthcare stock market has been a hotbed of excitement over the course of the past couple of years as companies across the healthcare industry have employed more nuanced approaches to how they offer care to patients. With the advent of new medical technologies and approaches to treating patients suffering from a myriad of diseases, news surrounding innovative companies putting their skills to the test in the healthcare industry has worked to attract investors looking for potential opportunities in the space. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Moleculin Biotech Inc (MBRX), Celldex Therapeutics Inc (CLDX), and Teladoc Health Inc (TDOC) represent four healthcare companies focused on innovating towards the future of healthcare.

  • GlobeNewswire2 months ago

    Moleculin Announces the FDA has Granted Orphan Drug Designation for its Brain Tumor Drug

    Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Status for its drug candidate WP1066 for the treatment of glioblastoma, the most aggressive form of brain tumor.

  • GlobeNewswire2 months ago

    Moleculin Announces Dr. James L. Abbruzzese, Chief of Medical Oncology Division at Duke University, Joins Science Advisory Board

    Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that Dr. James L. Abbruzzese, Chief of Oncology at Duke University has joined Moleculin’s Science Advisory Board. “We are honored to have Dr. Abbruzzese, a distinguished medical oncologist join our Science Advisory Board,” commented Walter Klemp, Moleculin’s Chairman and CEO.

  • GlobeNewswire2 months ago

    Moleculin Announces Patient Recruitment Begins in Annamycin Clinical Trial In Poland

    Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced it has begun in Poland recruiting patients in the Company’s second clinical trial to study Annamycin for the treatment of relapsed and refractory adults with acute myeloid leukemia (“AML”).

  • Amarin Down on Lower '19 View, Posts Preliminary '18 Results
    Zacks3 months ago

    Amarin Down on Lower '19 View, Posts Preliminary '18 Results

    Amarin (AMRN) reports preliminary results for 2018 and issues guidance for 2019. While the results exceeded estimates, outlook missed the same.

  • GlobeNewswire3 months ago

    Moleculin Announces Positive Data for its Pancreatic Cancer Drug Candidate

    Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that in preliminary animal studies, a second of its lead drugs, WP1732, has demonstrated enhanced activity in combination with checkpoint blockade antibodies in pancreatic cancer.

  • GlobeNewswire3 months ago

    Report: Exploring Fundamental Drivers Behind Cronos Group, Henry Schein, Argo Group International, Eiger BioPharmaceuticals, China Automotive, and Moleculin Biotech — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Dec. 31, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • ACCESSWIRE3 months ago

    Today's Research Reports on Trending Tickers: NeuroMetrix and Moleculin

    NEW YORK, NY / ACCESSWIRE / December 12, 2018 / NeuroMetrix and Moleculin were both up almost 19% in Tuesday’s trading session. Traders were gearing up for Moleculin’s conference call today discussing a recent discovery of a use of one of its molecules for cancer treatment while NeuroMetrix announced an update on its strategic collaboration with GSK Consumer Healthcare. NeuroMetrix, Inc. shares were up nearly 19% on almost 1.7 million shares traded on Tuesday.

  • GlobeNewswire3 months ago

    REMINDER: Moleculin Announces Conference Call to Discuss Recent Breakthrough Discovery and FDA Filing on Wednesday, December 12, 2018

    Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced a reminder it will host a conference call to discuss the recent discovery of a use of one of its molecules for cancer treatment and provide a business update. Participants can dial (800) 860-2442 or (412) 858-4600 to access the conference call, or can listen via a live Internet web cast, which is available in the Investor Relations section of the Company's website at www.moleculin.com. A webcast replay will be available in the Investors section of the Company’s website at www.moleculin.com for 90 days.

  • GlobeNewswire4 months ago

    Moleculin Announces Conference Call to Discuss FDA Filing and New Immune Checkpoint Data on Wednesday, December 12, 2018

    Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced it will host a conference call to discuss the recent discovery of a use of one its molecule for cancer treatment and provide a business update. Participants can dial (800) 860-2442 or (412) 858-4600 to access the conference call, or can listen via a live Internet web cast, which is available in the Investor Relations section of the Company's website at www.moleculin.com. A webcast replay will be available in the Investors section of the Company’s website at www.moleculin.com for 90 days.

  • GlobeNewswire4 months ago

    Moleculin Announces FDA Filing for Orphan Drug Designation for Glioblastoma Drug

    Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced it has filed a request with the U.S. Food and Drug Administration (“FDA”) for Orphan Drug Status for its drug candidate WP1066.

  • GlobeNewswire4 months ago

    Moleculin Announces Breakthrough Discovery for its WP1066

    Walter Klemp, Moleculin’s Chairman and CEO added, “This potential was initially reported in a 2017 Japanese study (Journal of clinical and experimental hematopathology, Vol. 57 No.1, 21-25, 2017), but we have now been able to confirm this activity with our own sponsored research at MD Anderson.  Also, very recent independent research (Front Pharmacol.